Scarica l'app Stockscreener
1.16
179.18%
0.7445
Dopo l'orario di chiusura:
.88
-0.28
-24.14%
Imunon Inc Borsa (IMNN) Ultime notizie
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules | IMNN Stock News - GuruFocus
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
DNA Immunotherapy Developer IMUNON Raises $9.75M to Advance Phase 3 Clinical Program - Stock Titan
Biotech Stock Surges To Close The Week After Major Announcement - The Globe and Mail
Big Gains For Imunon, Merus, And Douglas Elliman - Finimize
IMUNON’s Game-Changing Ovarian Cancer Data Sparks Massive Stock Surge – Here’s What You Need to Know! - RagingBull
Imunon Stock (IMNN) Rockets on Clinical Trial Results - TipRanks
Imunon shares soar on promising ovarian cancer trial results - Investing.com
Imunon shares soar on promising ovarian cancer trial results By Investing.com - Investing.com India
Imunon announces data from Phase 2 OVATION 2 study on IMNN-001 - TipRanks
Imunon Reports Prolonged Survival in Study of Potential Ovarian Cancer Treatment; Shares Soar Pre-Bell - marketscreener.com
IMNN Announces Promising Phase 2 Results for Ovarian Cancer Ther - GuruFocus
IMNN Announces Promising Phase 2 Results for Ovarian Cancer Therapy | IMNN Stock News - GuruFocus
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation High - GuruFocus
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer | IMNN Stock - GuruFocus
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation - GlobeNewswire
Breakthrough: New Ovarian Cancer Drug Extends Patient Survival by 13 Months in Groundbreaking Trial Results - Stock Titan
Retail Bulls Cheer Imunon’s Pullback From Public Offering, Citing ‘Much Better Funding Options’ By Stocktwits - Investing.com India
Imunon announces withdrawal of Form S-1 Registration Statement - TipRanks
IMUNON Announces Withdrawal of Form S-1 Registration Statement | - GuruFocus
Imunon (IMNN) Withdraws SEC Registration for Planned Public Offe - GuruFocus
IMUNON Announces Withdrawal of Form S-1 Registration Statement - GlobeNewswire
Phase 3 Biotech IMUNON Halts Public Offering Plans: What This Means for DNA Immunotherapy Pipeline - Stock Titan
Imunon Withdraws Registration Statement Impacting Strategy - TipRanks
Imunon withdraws public offering registration - Investing.com
Imunon faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Imunon (NASDAQ:IMNN) Rating Lowered to “Hold” at D Boral Capital - Defense World
Imunon Receives Nasdaq Non-Compliance Notice - TipRanks
Imunon faces Nasdaq delisting over equity shortfall - Investing.com
Imunon (NASDAQ:IMNN) Receives Hold Rating from D. Boral Capital - Defense World
IMNN Downgraded to Hold by D. Boral Capital Analyst Jason Kolber - GuruFocus
Imunon downgraded to Hold from Buy at D. Boral Capital - TipRanks
Imunon (IMNN) Downgraded Amid Concerns Over Financing Dilution | IMNN Stock News - GuruFocus
Zacks Small Cap Has Positive View of Imunon FY2025 Earnings - Defense World
HC Wainwright Has Positive Estimate for Imunon Q2 Earnings - Defense World
IMNN Unveils Promising Phase 1 Data for COVID-19 Vaccine Candida - GuruFocus
IMUNON Announces Six-Month Data Showing Durability of - GlobeNewswire
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment - MSN
Imunon announces new data from Phase 1 trial of IMNN-101 - TipRanks
IMUNON reports promising Phase 1 trial results for DNA vaccine By Investing.com - Investing.com Nigeria
IMUNON Announces Six-Month Data Showing Durability of Protection - GuruFocus
IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 - The Manila Times
IMUNON reports promising Phase 1 trial results for DNA vaccine - Investing.com
IMUNON, Inc. Presents Promising Phase 1 Data for IMNN-101 Vaccine, Highlighting Durability and Advantages Over mRNA Platforms - Nasdaq
CP NewsAlert: Enbridge sells stake in Westcoast pipeline to First Nations group - The Globe and Mail
New DNA Vaccine Outperforms mRNA: 6-Month COVID Protection After Single Dose - Stock Titan
D. Boral Capital Has Lowered Expectations for Imunon (NASDAQ:IMNN) Stock Price - Defense World
IMNN: First Site Activated for Phase 3 OVATION 3 Trial… - Zacks Small Cap Research
Imunon, Inc. (NASDAQ:IMNN) Q1 2025 Earnings Call Transcript - Insider Monkey
Imunon outlines 40% trial cost reduction and early readout potential as OVATION 3 Phase III launches - MSN
IMNN Stock Update: D. Boral Capital Lowers Price Target for Imun - GuruFocus
Imunon (IMNN) Price Target Reduced Amid Financial Concerns | IMN - GuruFocus
Imunon price target lowered to $17 from $29 at D. Boral Capital - TipRanks
Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Ad - GuruFocus
IMUNON, Inc. Reports Q1 2025 Financial Results and Clinical Progress - TipRanks
Imunon, Inc. Earnings Call: Clinical Progress Amid Financial Challenges - TipRanks
IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update | IMNN Stock News - GuruFocus
Earnings call transcript: Imunon Inc’s Q1 2025 results show EPS beat, stock rises - Investing.com Nigeria
IMUNON (IMNN) Advances Ovarian Cancer Treatment with Promising S - GuruFocus
17.27%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):